{"id":"W4365512785","doi":"10.1158/1538-7445.am2023-ct065","title":"Abstract CT065: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Medicine; Internal medicine; Capecitabine; Metastatic breast cancer; Oncology; Neratinib; Taxane; Trastuzumab; Progression-free survival; Breast cancer; Cancer; Colorectal cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001511861,0.0002859705,0.000742598,0.0007269868,0.000108299,0.00003958974,0.000221737,0.00007665129,0.0002452464],"category_scores_gemma":[0.0001667526,0.0002004617,0.00004930858,0.001802694,0.0004032137,0.0002359904,0.00004658245,0.0005393627,0.000002865602],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009397856,"about_ca_system_score_gemma":0.001662705,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002980981,"about_ca_topic_score_gemma":0.005070461,"domain_scores_codex":[0.9967862,0.000231736,0.0005831274,0.0006706642,0.0009356103,0.0007926133],"domain_scores_gemma":[0.9980524,0.0006681332,0.0001867896,0.0003690191,0.0005582267,0.0001654769],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6323249,0.00744025,0.009390674,0.0007471565,0.0003517133,0.0002400322,0.01209579,0.0001418231,0.002213136,0.00004680412,0.0002916378,0.3347161],"study_design_scores_gemma":[0.7603738,0.03273643,0.1621168,0.002506192,0.00007755279,0.00009651171,0.03644512,0.0007554727,0.002223444,0.000501191,0.001619648,0.0005478511],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853719,0.00129959,0.000008688935,0.003335788,0.0001073554,0.009651089,0.0001494098,0.0000473046,0.00002885598],"genre_scores_gemma":[0.9864342,0.001087563,0.0001118491,0.00005785322,0.0001155191,0.01154403,0.00002640365,0.00009062186,0.0005319397],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3341683,"threshold_uncertainty_score":0.817459,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1240011109960701,"score_gpt":0.4907828270774674,"score_spread":0.3667817160813973,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}